Metagenomi Therapeutics, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Metagenomi is a gene-editing biotechnology company developing therapies based on a suite of proprietary CRISPR and non-CRISPR gene-editing tools discovered through metagenomics research. It partners with larger pharmaceutical companies while also advancing its own pipeline of programs targeting genetic diseases in areas such as liver disease and immuno-oncology.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Reid LaurenceInsider | Buy | $23K | 19,883at $1.17 | Sep 9, 2026 |
| Reid LaurenceInsider | Buy | $138 | 117at $1.18 | Sep 9, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable MGX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.